Guided Therapeutics Answers FDA Questions for LuViva™ Advanced Cervical Scan PMA

Guided Therapeutics, Inc. GTHP today announced that it has answered all key questions from the U.S. Food and Drug Administration (FDA) regarding the company's premarket approval application for the LuViva™ Advanced Cervical Scan. “We are pleased to provide the FDA with the additional information the agency requested and within the time period required to maintain the PMA application under active review,” said Mark L. Faupel, Ph.D., President and CEO of Guided Therapeutics. “The FDA will review our submission, we hope move forward with the PMA process and schedule a panel meeting date, although the agency has the option to ask for additional information.”
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: News
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!